Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
NEW YORK, Aug. 10, 2017 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:
- 2017 Wedbush PacGrow Healthcare Conference on August 16, 2017 at 9:10 a.m. Eastern Time
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 [email protected] Media inquiries: [email protected] Investor inquiries: [email protected]
